Amgen Breakthrough: Lung Cancer Treatment Extends Survival by 58%
Imagine a cancer treatment that increases a patient's survival rate by a staggering 58% in just 21 months. A groundbreaking study has revealed that a combination of Amgen's Imdelltra and AstraZeneca's Imfinzi can significantly extend the life of those suffering from aggressive lung cancer. This remarkable discovery has the potential to transform the standard of care for patients, making one of the most aggressive cancers a chronic disease. With sales of Imdelltra already reaching $288 million, this breakthrough could open up new commercial opportunities for Amgen. As Dr. Paul Burton puts it, "these data say that's a possibility." Don't miss this incredible story of medical advancement. To stay up-to-date on the latest news and breakthroughs, be sure to subscribe to our channel.
Tags/Hashtags: #amgen #astrazeneca #immunotherapy #imdelltra #imfinzi #amgen #astrazeneca
Leave a Reply